Jump to: navigation, search
Pentoxyverine skeletal.png
Clinical data
AHFS/Drugs.comInternational Drug Names
  • No studies; contraindicated
Routes of
Oral, rectal
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life2.3 hours (oral), 3–3.5 hours (rectal)
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass333.465 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Pentoxyverine


Most recent articles on Pentoxyverine

Most cited articles on Pentoxyverine

Review articles on Pentoxyverine

Articles on Pentoxyverine in N Eng J Med, Lancet, BMJ


Powerpoint slides on Pentoxyverine

Images of Pentoxyverine

Photos of Pentoxyverine

Podcasts & MP3s on Pentoxyverine

Videos on Pentoxyverine

Evidence Based Medicine

Cochrane Collaboration on Pentoxyverine

Bandolier on Pentoxyverine

TRIP on Pentoxyverine

Clinical Trials

Ongoing Trials on Pentoxyverine at Clinical

Trial results on Pentoxyverine

Clinical Trials on Pentoxyverine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Pentoxyverine

NICE Guidance on Pentoxyverine


FDA on Pentoxyverine

CDC on Pentoxyverine


Books on Pentoxyverine


Pentoxyverine in the news

Be alerted to news on Pentoxyverine

News trends on Pentoxyverine


Blogs on Pentoxyverine


Definitions of Pentoxyverine

Patient Resources / Community

Patient resources on Pentoxyverine

Discussion groups on Pentoxyverine

Patient Handouts on Pentoxyverine

Directions to Hospitals Treating Pentoxyverine

Risk calculators and risk factors for Pentoxyverine

Healthcare Provider Resources

Symptoms of Pentoxyverine

Causes & Risk Factors for Pentoxyverine

Diagnostic studies for Pentoxyverine

Treatment of Pentoxyverine

Continuing Medical Education (CME)

CME Programs on Pentoxyverine


Pentoxyverine en Espanol

Pentoxyverine en Francais


Pentoxyverine in the Marketplace

Patents on Pentoxyverine

Experimental / Informatics

List of terms related to Pentoxyverine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Pentoxyverine (rINN) or carbetapentane is an antitussive (cough suppressant) commonly used for cough associated with illnesses like common cold. It is sold over-the-counter in the United States as Solotuss,[1] or in combination with other medications, especially decongestants. One such product is Certuss, a combination of guaifenesin and pentoxyverine.[2]

The drug is available in the form of drops, suspensions and suppositories.[1][3]


The drug is used for the treatment of dry cough associated with conditions such as common cold, bronchitis or sinusitis. Like codeine and other antitussives, it relieves the symptom, but does not heal the illness.[1] No controlled clinical trials regarding the efficiency of pentoyxverine are available.[4]

Pharmacologists use the substance as a selective agonist at the sigma-1 receptor in animal[5] and in vitro experiments.[6][7]


Pentoxyverine is contraindicated in persons with bronchial asthma[4] or other kinds of respiratory insufficiency (breathing difficulties), as well as angle-closure glaucoma. No data are available for the use of pentoxyverine during pregnancy, lactation, or children under two years of age, wherefore the drug must not be used under these circumstances.[3]

Antitussive drugs are not useful in patients with extensive phlegm production because they prevent coughing up the phlegm.[4]

Adverse effects

The most common side effects (seen in more than 1% of patients) are upper abdominal (belly) pain, diarrhoea, dry mouth, and nausea or vomiting. Allergic reactions of the skin like itching, rashes, hives and angiooedema are rare. The same is true for anaphylactic shock and convulsions.[3][8]


Overdosage leads to drowsiness, agitation, nausea and anticholinergic effects like tachycardia (high heart rate), dry mouth, blurred vision, glaucoma, or urinary retention.[1][3] Especially in children, pentoxyverine can cause hypoventilation,[4] but much more seldom than codeine and other opioid antitussives.

The treatment of overdosage aims at the symptoms; there are no specific antidotes available.[3]


No interactions have been described at usual doses. It is possible that pentoxyverine can increase the potency of sedative drugs like benzodiazepines, some anticonvulsants and antidepressants, and alcohol. Likewise, some consumer informations warn patients from taking the drug in combination with or up to two weeks after monoamine oxidase inhibitors, which are known to cause potentially fatal reactions in combination with the (chemically only distantly related) antitussive dextromethorphan.[1][3][4]

Mechanism of action

Pentoxyverine suppresses the cough reflex in the central nervous system,[1] but the exact mechanism of action is not known with certainty. The drug acts as an antagonist at muscarinic receptors[3] (subtype M1) and as an agonist at sigma receptors (subtype σ1).[5] Its anticholinergic properties can theoretically relax the pulmonary alveoli and reduce phlegm production. Spasmolytic and local anaesthetic properties have also been described.[4] The clinical relevance of these mechanisms is uncertain.


The substance is absorbed quickly from the gut and reaches its maximum plasma concentration (Cmax) after about two hours. If applied rectally, Cmax is reached after four hours. The bioavailability of the suppositories, measured as area under the curve (AUC), is about twofold that of oral formulations, due to a first pass effect of over 50%. By far the most important metabolisation reaction is ester hydrolysis, which accounts for 26.3% of the total clearance through the kidneys. Only 0.37% are cleared in form of the original substance.[3] The plasma half life is 2.3 hours for oral formulations and three to 3.5 hours for suppositories.[9] Pentoxyverine is also excreted into the breast milk.[3]

Chemical properties

Pentoxyverine dihydrogen citrate, the salt that is commonly used for oral preparations, is a white to off-white, crystalline powder. It dissolves easily in water or chloroform, but not in benzene, diethyl ether, or petroleum ether, and melts at 90–95 °C.[4] Other orally available salts are the hydrochloride and the tannate;[10] suppositories contain the free base.[3]


  1. 1.0 1.1 1.2 1.3 1.4 1.5 "Carbetapentane".
  2. "Certuss".
  3. 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 Jasek, W., ed. (2008). Austria-Codex (in German) (63 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 978-3-85200-188-3.
  4. 4.0 4.1 4.2 4.3 4.4 4.5 4.6 Dinnendahl, V.; Fricke, U., eds. (2010). Arzneistoff-Profile (in German). 4 (23 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. ISBN 978-3-7741-9846-3.
  5. 5.0 5.1 PMID 14691051 (PMID 14691051)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  6. PMID 12445574 (PMID 12445574)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  7. "Carbetapentane Citrate CAS#: 23142-01-0". Chemicalbook.
  8. Dootz, H.; Kuhlmann, A.; Hoffmann, K. (eds.). Rote Liste (in German) (2005 ed.). Aulendorf: Editio Cantor. 24 037. ISBN 3-87193-306-6.
  9. Steinhilber, D.; Schubert-Zsilavecz, M.; Roth, H. J. (2005). Medizinische Chemie (in German). Stuttgart: Deutscher Apothekerverlag. p. 190. ISBN 3-7692-3483-9. Unknown parameter |trans_title= ignored (help)
  10. "Pentoxyverine Full Prescribing Information". MIMS.